Reduction in Nitric Oxide Bioavailability Shifts Serum Lipid Content Towards Atherogenic Lipoprotein in Rats. Biomedicine and pharmacotherapy

Abstract

Nitric oxide (NO) is major endothelial relaxing factor and reduction in its bioavailabilty has been linked to hypertension. Furthermore, high lipid content is a strong risk factor predisposing to cardiovascular diseases. The principal focus of this study was to investigate the effect of blockade of nitric oxide synthase (NUS) on serum lipid content in rats. Male Wistar rats (150-170g, a 15) were randomly divided into two gruupe designated control (n=5), and L-Name group (n-10) and were gavage with distilled water and 60 mg/kg of L-NAME respectively daily for three weeks. After 3 weeks, the L-NAME group was sub-divided into two sub-groups (n=5 each): 1-NAME (00 mg/kg of L-NAME), and L-NAME plus ramipril (LR) (60 mg/kg of L-NAME plus 20 mg/kg of ramipril) and were treated daily for another three weeks. The blood pressure (BP) of the conscious rats was measured by tail-cuft method at the onset, at the third and at the sixth weeks of the experiment; while serum lipid contents and NO were measured at the third and sixth weeks. At the end of the experiment blood sample was drawn by ocular puncture for evaluation of lipid profile and NO, and the animals were later euthanized by overdere of anesthesia. Data were analyzed using ANOVA at p < 0.05. There was a significant increase in HP, triglyceride, total cholesterol, low density lipoprotein-cholesterol, and atherogenic indices in L-NAME group compared to the control and LR group (p<0.05); NO and high density lipoprotein cholesterol was significant lower in the L-NAME group compared to contral and LR (p<0.05). In conclusion, reduction in NO bioavail- ability alters lipid metabolism, which was rected by ramipril